|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.03 USD | +1.38% |
|
+5.45% | -1.78% |
| Apr. 05 | Arbutus Biopharma Obtains Favorable Court Order in Moderna Patent Lawsuit | MT |
| Apr. 04 | Moderna Suffers Setback in Lawsuit by Arbutus | MT |
SK Biopharmaceuticals Co., Ltd. (KOSE:A326030) agreed to acquire 60% interest in ProteoVant Sciences, Inc. from Roivant Sciences Ltd. (NasdaqGM:ROIV) for $47.5 million on June 29, 2023. As for consideration, SK Biopharmaceuticals Co., Ltd. would acquire 40 million shares of Proteovant valued at about $47.5 million. The transaction is expected to close on July 17, 2023.
As of July 17, 2023, the transaction is expected to close on August 31, 2023.
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 83,500 KRW | +0.24% | +0.97% | 4.75B | ||
| 11.03 USD | +1.38% | +5.45% | 8.89B | ||
| 1st Jan change | Capi. | |
|---|---|---|
| -1.78% | 8.89B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
ROIVANT SCIENCES LTD. 
